Theralite dialysis membrane launched; could restore kidney function in cancer patients
This article was originally published in Clinica
Executive Summary
Gambro has launched Theralite, a semi-permeable membrane intended to filter harmful proteins out of cancer patients' blood. It is designed to be employed in a form of dialysis to treat the acute kidney failure often seen in patients with multiple myeloma (MM), and Gambro believes it can actually reverse the progression of kidney failure.
You may also be interested in...
Normality Reasserts Itself For Biotech IPOs
The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.
MRM Health Pulls A Pouchitis Hit Out Of The Bag
The mid-stage success is encouraging, but taking on Takeda won’t be easy.
Novartis Draws Out Its APPLAUSE
Another data drop from Fabhalta’s IgAN trial looks encouraging, despite a missing abstract.